BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Friday, July 18, 2025
Home » Topics » Analysis and data insight

Analysis and data insight
Analysis and data insight RSS Feed RSS

Coronavirus and stock charts

As the world grows weary of COVID-19, so do infectious disease investors

Jan. 27, 2022
By Karen Carey
While BioWorld’s Infectious Disease Index showed a huge 144% climb in 2020, an enthusiastic response toward defeating the SARS-CoV-2 virus, the index dropped significantly in early 2021 and spent most of the year spiking up and down, reacting abruptly to the promises of herd immunity and the threats of vaccine-resistant variants.
Read More
Syringe and capsules atop lab chart

Despite a busy 2021, clinical data slows to pre-pandemic levels

Jan. 25, 2022
By Karen Carey
The amount of clinical data reported in January so far is currently 30% below the amount reported during the same month last year, which was the slowest month of 2021.
Read More

Biggest gainers and losers for the week of Jan. 17-21, 2022

Jan. 21, 2022
The top 10 biopharma stock gainers and losers for the week.
Read More
Handshake with digital globe overlay

Digital health dominated med-tech deal activity and drove record M&As in 2021

Jan. 21, 2022
By Karen Carey
In one of the most extraordinary years for med-tech mergers and acquisitions, 2021 is the culmination of a snowballing interest in maturing digital technologies amid mounting COVID-19 pandemic problems and uncertain futures. Societal lockdowns in 2020 boosted notice of telehealth, testing and remote monitoring devices, but that notice ramped up even more in 2021, not only as new SARs-CoV-2 variants emerged, but as businesses sought innovative ways of delivering their products.
Read More

Biopharma money raised: Jan. 1-20, 2022

Jan. 21, 2022
Year-to-date money raised in public, private and other financings of biopharma companies.
Read More

Money raised by biopharma: 2022 vs. 2021 vs. 2020 vs. 2019

Jan. 21, 2022
Total raised in public, private and other financings of biopharma companies, comparing 2022 vs. 2021 vs. 2020 vs. 2019.
Read More

Med-tech gainers and losers for Jan. 18-21, 2022

Jan. 21, 2022
The top 10 med-tech stock gainers and losers for the week.
Read More
Hand holding gear, dollar sign

Med-tech IPOs, VC rounds hit records in 2021; overall financings down 17%

Jan. 19, 2022
By Karen Carey
While med-tech financings in 2021 fell about 17% below the amount raised in 2020, the industry still collected $49.26 billion, significantly more than each of the two previous years, and driven primarily by digital health and diagnostic technologies.
Read More

Biggest gainers and losers for the week of Jan. 10-14, 2022

Jan. 14, 2022
The top 10 biopharma stock gainers and losers for the week.
Read More

Biopharma money raised: Jan. 1-13, 2022

Jan. 14, 2022
Year-to-date money raised in public, private and other financings of biopharma companies.
Read More
Previous 1 2 … 149 150 151 152 153 154 155 156 157 … 268 269 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for July 17, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for July 17, 2025.
  • Multiple myeloma and antibodies

    Blenrep misstep? ODAC cites tox, GSK dosing neglect in MM

    BioWorld
    The rough ride presaged by briefing documents came to pass for GSK plc with the drug first approved by the U.S. FDA as Blenrep (belantamab mafodotin, bel-maf), as...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for July 15, 2025
  • Brain and neural networks

    Proteomics finds surprise commonalities as well as differences in neurodegenerative diseases

    BioWorld
    The switch will be flicked today to make the world’s largest dementia-related proteomics dataset freely available to researchers, at the same time as members of...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing